Compare OPAL & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAL | BEAT |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Retail: Computer Software & Peripheral Equipment |
| Sector | Utilities | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.3M | 84.0M |
| IPO Year | N/A | 2021 |
| Metric | OPAL | BEAT |
|---|---|---|
| Price | $2.18 | $2.40 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $2.81 | ★ $6.75 |
| AVG Volume (30 Days) | 386.4K | ★ 32.1M |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $329,243,000.00 | N/A |
| Revenue This Year | $17.15 | N/A |
| Revenue Next Year | $22.04 | N/A |
| P/E Ratio | $95.04 | ★ N/A |
| Revenue Growth | ★ 7.26 | N/A |
| 52 Week Low | $1.26 | $0.54 |
| 52 Week High | $4.08 | $4.00 |
| Indicator | OPAL | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 45.03 | 55.19 |
| Support Level | $2.12 | $2.38 |
| Resistance Level | $2.87 | $2.88 |
| Average True Range (ATR) | 0.19 | 0.32 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 27.01 | 24.51 |
OPAL Fuels Inc is a fully integrated, nationwide leader in the production and distribution of low-carbon intensity renewable natural gas. The company is also engaged in the marketing and distribution of RNG to heavy-duty trucking and other hard-to-de-carbonize industrial sectors. The company designs, develops, constructs, operates, and services Fueling Stations for trucking fleets across the country that use natural gas to displace diesel as their transportation fuel. The company derives revenue from the sale of Renewable Power, design, development, construction, and service of Fueling Stations, and sales of RNG produced by OPAL and third parties as pipeline-quality natural gas.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.